Zobrazeno 1 - 10
of 799
pro vyhledávání: '"Roman, Hájek"'
Autor:
Zhongfei Tao, Zuzana Chyra, Jana Kotulová, Piotr Celichowski, Jana Mihályová, Sandra Charvátová, Roman Hájek
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment paradigms for hematological malignancies. However, more than half of these patients cannot achieve sustainable tumor control, partially due to the inadequate pot
Externí odkaz:
https://doaj.org/article/3e3d19d829fc46a7bb5eefac35652935
Autor:
Monika Vlachová, Lukáš Pečinka, Jana Gregorová, Lukáš Moráň, Tereza Růžičková, Petra Kovačovicová, Martina Almáši, Luděk Pour, Martin Štork, Roman Hájek, Tomáš Jelínek, Tereza Popková, Marek Večeřa, Josef Havel, Petr Vaňhara, Sabina Ševčíková
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Multiple myeloma (MM) is the second most prevalent hematological malignancy, characterized by infiltration of the bone marrow by malignant plasma cells. Extramedullary disease (EMD) represents a more aggressive condition involving the migrat
Externí odkaz:
https://doaj.org/article/123756e52c444a3ba9395eee02fa6b55
Autor:
Ecenur Guder Arslan, Kwee Yong, Thomas Martın, Meletios Dımopoulos, Joseph Mıkhael, Marcelo Capra, Thierry Facon, Roman Hájek, Ivan Špıčka, Ross Baker, Kihyun Kım, Gracia Martınez, Chang-Ki Mın, Philippe Moreau
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 45, Iss , Pp S14-S15 (2023)
Objective: Isatuximab (Isa, anti-CD38 monoclonal antibody) is approved in combination with carfilzomib (K) and dexamethasone (d), for relapsed multiple myeloma (MM) patients (pts) after ≥1 prior therapy. Final progression free survival (PFS) analys
Externí odkaz:
https://doaj.org/article/5bf335a963004c8aafd92c9904acdefe
Autor:
Piotr Celichowski, Marcello Turi, Sandra Charvátová, Dhwani Radhakrishnan, Neda Feizi, Zuzana Chyra, Michal Šimíček, Tomáš Jelínek, Juli Rodriguez Bago, Roman Hájek, Matouš Hrdinka
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-23 (2023)
Abstract Cancer immunotherapies utilizing genetically engineered T cells have emerged as powerful personalized therapeutic agents showing dramatic preclinical and clinical results, particularly in hematological malignancies. Ectopically expressed chi
Externí odkaz:
https://doaj.org/article/1d5b44d5e5a746e6967cb1d46fd3f1a9
Publikováno v:
Case Reports in Oncology, Vol 16, Iss 1, Pp 143-150 (2023)
Telemonitoring is a great tool for vital signs monitoring in patients at high risk of severe life-threatening infections, such as haemato-oncological patients. As it can detect early symptoms of an infection, it allows early reaction and, therefore,
Externí odkaz:
https://doaj.org/article/71c907b8b1b247b3b13b077e30ee9675
Autor:
Daisuke Ogiya, Zuzana Chyra, Sigitas J. Verselis, Morgan O’Keefe, Jacquelyn Cobb, Ivane Abiatari, Srikanth Talluri, Anjana Anilkumar Sithara, Teru Hideshima, Michael P. Chu, Roman Hájek, David M. Dorfman, Linda M. Pilarski, Kenneth C. Anderson, Sophia Adamia
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Novel drug discoveries have shifted the treatment paradigms of most hematological malignancies, including multiple myeloma (MM). However, this plasma cell malignancy remains incurable, and novel therapies are therefore urgently needed. Whole
Externí odkaz:
https://doaj.org/article/0720ebfef4374a3d981cb2d875066c2e
Autor:
Giovanni Palladini, Stefan Schönland, Giampaolo Merlini, Paolo Milani, Arnaud Jaccard, Frank Bridoux, Meletios A. Dimopoulos, Sriram Ravichandran, Ute Hegenbart, Wilfried Roeloffzen, M. Teresa Cibeira, Hermine Agis, Monique C. Minnema, Rui Bergantim, Roman Hájek, Cristina João, Alexandros Leonidakis, Giorgos Cheliotis, Pieter Sonneveld, Efstathios Kastritis, Ashutosh Wechalekar
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-8 (2023)
Abstract Systemic light-chain (AL) amyloidosis is a rare and debilitating disease. Advances have been made in new treatments in recent years, yet real-world data on the management of the disease are scarce. EMN23 is a retrospective, observational stu
Externí odkaz:
https://doaj.org/article/b66ddf1ad30c445e87c57bf515f577a5
Autor:
Enrique M. Ocio, Yvonne A. Efebera, Roman Hájek, Jan Straub, Vladimir Maisnar, Jean-Richard Eveillard, Lionel Karlin, María-Victoria Mateos, Albert Oriol, Vincent Ribrag, Paul G. Richardson, Stefan Norin, Jakob Obermüller, Nicolaas A. Bakker, Luděk Pour
Publikováno v:
Haematologica, Vol 109, Iss 3 (2023)
Melphalan flufenamide (melflufen), a first-in-class, alkylating peptide-drug conjugate, demonstrated clinical benefit in combination with dexamethasone in triple-class refractory multiple myeloma (MM). The phase I/IIa ANCHOR study evaluated melflufen
Externí odkaz:
https://doaj.org/article/2fc23bce08c444d98389254c7b7873ab
Autor:
Luděk Pour, Monika Szarejko, Jelena Bila, Fredrik H. Schjesvold, Ivan Spicka, Vladimir Maisnar, Artur Jurczyszyn, Zhanet Grudeva-Popova, Roman Hájek, Ganna Usenko, Marcus Thuresson, Stefan Norin, Sara Jarefors, Nicolaas A. Bakker, Paul G. Richardson, Maria-Victoria Mateos
Publikováno v:
Haematologica, Vol 109, Iss 3 (2023)
Melphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, plus dexamethasone was approved in Europe for use in patients with triple-class refractory relapsed/refractory multiple myeloma (RRMM) with ≥3 prior lines of the
Externí odkaz:
https://doaj.org/article/0bf9f72785bc4d0cad26c30e6349239e
Autor:
John C. Byrd, Seema Ali Bhat, Farrukh Awan, Pratyush Giri, Sumita Ratnasingam, Roman Hájek, Dagmar Hess, Daniela Alves, Jan Maciej Zaucha, Annalise Shen, Elizabeth Bilotti, Jesse Mcgreivy, Wayne P. Rothbaum, Hanna Ciepluch
Publikováno v:
HemaSphere, Vol 7, p e197904a (2023)
Externí odkaz:
https://doaj.org/article/8da8cf41c62841f09bec7dcbf3d95b7f